5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
Recruiting · NCT07044310 · Registry updated 2026-08-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss | Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, breast carcinoma in situ, breast disorder, breast neoplasm, carcinoma, epithelial neoplasm, in situ carcinoma, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-08-10 | NCT07044310 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Mayo Clinic | 970 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Mayo Clinic in Florida | Jacksonville | United States | 224 |